Skip to content

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city.

MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients.

According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease.

Albert Gutierrez, CEO of MedPharm, sees Alzheimer’s as “one of the biggest things that’s plaguing our country now and in the future.” That’s why he’s excited about cannabis’ potential to treat it.

Read Full Article Here

Stories you may be interested in

Substance in cannabis ‘could boost pancreatic cancer treatments’

A substance found in cannabis plants might boost treatments for patients with pancreatic cancer, research in mice has suggested. Cannabidiol, or CBD, is not psychoactive, meaning it does not produce feelings of being high in those who take it. It is extracted from hemp plants and is legal in the UK, although a CBD product…
Read More

Arfinn Med March Updates

We are very happy to announce the release of several new functions within the Arfinn Med Platform.  Those include: * Text message updates from patients regarding their treatments * Templating for exam notes  * Updated analytics and dosing reports * Google calendar and Calendly integrations to schedule appointments. Please view the video below for more…
Read More

Medical Marijuana Faces Acceptance Barrier by Hesitant Medical Schools

A new study shows a growing interest by university pharmacy programs in teaching about medical marijuana in their curriculum, while medical schools seem to lag behind. Sixty-two percent of U.S. pharmacy school respondents queried in a new survey said they included medical marijuana in their doctorate of pharmacy curriculum. That’s according to a nine-page study co-authored by…
Read More

New Features

As Arfinn Med has become the leading Electronic Medical Record (EMR) and practice management solution for medical cannabis clinics, we have continued to release new features to help improve clinical workflows and patient care. Our newest feature is a custom intake form builder to help gather pertinent patient information prior to appointments. INTAKE FORM BUILDER…
Read More

Military Times: “Our veterans deserve the well-being that medical cannabis can provide.”

The physical and mental trauma that veterans experience as a result of their military service extends far beyond the end of their participation in combat-related roles. To recognize the sacrifices veterans have made to protect our country, state and federal lawmakers must continue to expand access to crucial treatment options and programs that assist veterans…
Read More

DeSantis OKs telehealth for Florida medical marijuana patients

TAMPA, Fla. (WFLA) — Florida Gov. Ron DeSantis signed a bill allowing the state’s 828,000 medical marijuana patients to use telehealth to visit their doctors. On Monday, DeSantis signed HB-387, titled “Medical Use of Marijuana,” which allows patients renewing their medical marijuana recommendation to meet with their doctors online. Currently, patients must visit their doctor in person…
Read More

Leave a Comment

You must be logged in to post a comment.